Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A

por Retout, Sylvie, Schmitt, Christophe, Petry, Claire, Mercier, François, Frey, Nicolas
Publicado 2020

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

por Jonsson, Fredrik, Schmitt, Christophe, Petry, Claire, Mercier, Francois, Frey, Nicolas, Retout, Sylvie
Publicado 2021

A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A

por Yoneyama, Koichiro, Schmitt, Christophe, Chang, Tiffany, Dhalluin, Christophe, Nagami, Sayaka, Petry, Claire, Levy, Gallia G.
Publicado 2021

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

por Schmitt, Christophe, Adamkewicz, Joanne I., Xu, Jin, Petry, Claire, Catalani, Olivier, Young, Guy, Negrier, Claude, Callaghan, Michael U., Levy, Gallia G.
Publicado 2021

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects

por Li, Haiyan, Zhang, Weijiang, Petry, Claire, Li, Lindong, Fernandez, Elena, Kiialainen, Anna, Feng, Sheng, Hsu, Wanling, Li, Li, Wei, Yudong, Schmitt, Christophe
Publicado 2020

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

por Gibiansky, Ekaterina, Petry, Claire, Mercier, Francois, Günther, Andreas, Herman, Ann, Kappos, Ludwig, Hauser, Stephen, Yamamoto, Yumi, Wang, Qing, Model, Fabian, Kletzl, Heidemarie
Publicado 2020

Low immunogenicity of emicizumab in persons with haemophilia A

por Schmitt, Christophe, Emrich, Thomas, Chebon, Sammy, Fernandez, Elena, Petry, Claire, Yoneyama, Koichiro, Kiialainen, Anna, Howard, Monet, Niggli, Markus, Paz‐Priel, Ido, Chang, Tiffany
Publicado 2021

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A

por Schmitt, Christophe, Mancuso, Maria Elisa, Chang, Tiffany, Podolak‐Dawidziak, Maria, Petry, Claire, Sidonio Jr, Robert, Yoneyama, Koichiro, Key, Nigel S., Niggli, Markus, Lehle, Michaela, Peyvandi, Flora, Oldenburg, Johannes
Publicado 2022

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis

por Hauser, Stephen L., Bar-Or, Amit, Weber, Martin S., Kletzl, Heidemarie, Günther, Andreas, Manfrini, Marianna, Model, Fabian, Mercier, Francois, Petry, Claire, Wing, Qing, Koendgen, Harold, Smith, Terence, Kappos, Ludwig
Publicado 2023

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors

por Italiano, Antoine, Miller, Wilson H., Blay, Jean-Yves, Gietema, Jourik A., Bang, Yung-Jue, Mileshkin, Linda R., Hirte, Hal W., Higgins, Brian, Blotner, Steven, Nichols, Gwen L., Chen, Lin Chi, Petry, Claire, Yang, Qi Joy, Schmitt, Christophe, Jamois, Candice, Siu, Lillian L.
Publicado 2021